(MedPage Today) — The FDA issued a warning letter to Novo Nordisk for failing to report and investigate potentially serious side effects associated with its popular GLP-1 medications.
In a letter dated March 5 and made public on Tuesday, the…
Source link : https://www.medpagetoday.com/publichealthpolicy/fdageneral/120262
Author :
Publish date : 2026-03-11 21:11:00
Copyright for syndicated content belongs to the linked Source.
